Search the Newsreel

Insulet (PODD) Is Down 15.9% After Cutting 2026 Revenue Guidance on Type 2 Retention Strains

Insulet Corporation (PODD) saw its stock drop 21.9% after cutting its 2026 revenue outlook due to weaker retention and utilization among Type 2 diabetes users, despite strong overall Omnipod growth. The company reported Q2 2026 sales of US$801.7 million and net income of US$95.0 …

Earnings To Watch: Bowman Consulting Group Ltd (BWMN) Q2 2026 -- GF Value Sees 64% Upside

Bowman Consulting Group Ltd (BWMN) is preparing to release its Q2 2026 earnings on August 10, 2026, with revenue estimated at $138.64 million and EPS at $0.29. Despite a slight decline in 2026 revenue and earnings estimates over the past 90 days, the company's …

FTI Consulting : Capital Advisors Advise Ooredoo Group on AI Compute Expansion Through Investment in Zankore Alongside Indosat Ooredoo Hutchison, NVIDIA and Nokia

FTI Capital Advisors (FTICA) advised Ooredoo Group on its strategic investment in Zankore, an Indonesian company specializing in AI compute and neocloud platforms. Ooredoo Group, a founding shareholder with a 49% stake, will invest approximately US$800 million to launch and develop Zankore. This investment, …

Earnings call transcript: Sula Vineyards posts Q1 2026 revenue beat, shares fall

12 Compass Lexecon Experts Named Among Top 5% of Practitioners

FTI Consulting announced that its subsidiary, Compass Lexecon, was recognized as the top global economic consulting firm in the Lexology Index: Competition 2026, with 65 competition economists and future leaders. Additionally, 12 Compass Lexecon professionals were named Global Elite Thought Leaders, placing them among …

Compass Lexecon Ranked Top Economic Consulting Firm on Lexology Index Competition 2026 List

Compass Lexecon, a subsidiary of FTI Consulting, has been recognized as the top economic consulting firm on the Lexology Index: Competition 2026 list. Sixty-five of its professionals were named, with twelve also distinguished as Global Elite Thought Leaders, placing them among the top 5% …

PODD Shareholder Alert: August 31, 2026 Lead Plaintiff Deadline in Insulet Corporation Securities Class Action - Contact SueWallSt

This article announces a lead plaintiff deadline of August 31, 2026, for a securities class action lawsuit against Insulet Corporation (NASDAQ: PODD). The lawsuit alleges that Insulet made misleading statements regarding its manufacturing quality after two voluntary medical device corrections led to significant drops …

Sula Vineyards' Q1 profit slumps 45 pc as margins shrink

Secmark Consultancy Ltd Downgraded to Sell Amid Technical and Valuation Concerns

Insulet (PODD) Stock Looks Undervalued As The Market Stays Cautious

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Insulet stock has fallen sharply over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to …

Revenue Transformation Improves Commercial Performance

FTI Consulting helped an addiction treatment provider optimize its commercial operations, leading to significant cost reductions and revenue growth. By implementing initiatives across marketing, call center operations, business development, and patient intake, the provider achieved approximately $9 million in cost savings and generated $7 …

Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA)

This article highlights two healthcare stocks, Insulet (PODD) and Entrada Therapeutics Inc (TRDA), which have received bullish sentiments from analysts. Steven Lichtman of William Blair maintained a Buy rating on Insulet, while Myles Minter, also from William Blair, maintained a Buy rating on Entrada …

Insulet Valuation Attractive Despite Growth Reset Risk, RBC Says

RBC views Insulet's valuation as attractive despite potential risks associated with its growth strategy and upcoming competition. The article briefly mentions Insulet's challenges in serving Type 2 diabetes patients. Full access to the MT Newswires article requires a premium subscription.

Huron Consulting Group Inc. $HURN Shares Sold by Royal Bank of Canada

Royal Bank of Canada decreased its holdings in Huron Consulting Group Inc. (NASDAQ:HURN) by 15.1% in the first quarter, selling 27,629 shares. Despite this, other institutional investors increased their positions, and company insiders sold shares worth $4.37 million. Huron Consulting Group reported strong quarterly …

California State Teachers Retirement System Acquires 6,532 Shares of FTI Consulting, Inc. $FCN

The California State Teachers Retirement System increased its stake in FTI Consulting (NYSE:FCN) by 21.4% in the first quarter, acquiring an additional 6,532 shares, bringing its total holdings to 37,024 shares valued at $6.5 million. This move is part of broader institutional investor activity, …

Sula Vineyards publishes Q1FY26 results in newspapers after board approval

FMR LLC discloses 13.7% Bowman Consulting stake in 13G/A for BWMN

FMR LLC and Abigail P. Johnson have disclosed a significant ownership stake in Bowman Consulting Group Ltd. through an Amendment No. 3 to a Schedule 13G filing. FMR LLC beneficially owns 2,399,322 shares, representing 13.7% of the common stock, with sole dispositive power over …

FMR LLC (FCN) discloses 1.21M FTI Consulting shares, 4% beneficial stake

FMR LLC has filed an amended Schedule 13G, disclosing a 4.0% beneficial ownership stake in FTI Consulting Inc. (FCN), totaling 1,210,542.05 shares. The filing indicates FMR LLC holds sole voting power over 1,206,834 shares and sole dispositive power over all 1,210,542.05 shares. Abigail P. …

Insulet Corp (PODD) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth Offset by Type 2 ...

Insulet Corp (PODD) reported strong Q2 2026 revenue growth of 23.5%, exceeding expectations, driven by demand for its Omnipod product. However, the company lowered its full-year U.S. Omnipod growth outlook due to worse-than-anticipated retention and utilization trends among Type 2 diabetes patients, which it …

Insulet Corporation Stock 12‑Month Price Target Cut to $225.45, Implies 35% Upside

Analysts have lowered the 12-month average price target for Insulet Corporation (PODD) stock from $232.3 to $225.45, with a range of $160 to $294 per share. This new target implies a 35% potential upside based on the Aug. 4 closing price. Despite the target …

FTI Consulting UK Public Affairs Snapshot: What the Burnham Government Means for Health and Life Sciences

New Prime Minister Andy Burnham, a former Health Secretary, is expected to prioritize health policy, with a focus on health devolution, prevention, and social care reform, drawing from his experience as Greater Manchester Mayor. While his administration aims to champion science and innovation, recent …

Huron Consulting Group Inc. $HURN Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC reduced its stake in Huron Consulting Group Inc. ($HURN) by 20.4% in the first quarter, selling 13,370 shares but still retaining 52,312 shares valued at $6.67 million. Despite this sale, institutional investors and hedge funds collectively own 93.9% of Huron's …

Odigma Consultancy Solutions Ltd Reports Positive Financial Trend Amidst Prolonged Market Challenges

Huron Consulting Group Inc. (NASDAQ:HURN) Receives Average Rating of "Buy" from Analysts

Huron Consulting Group Inc. (NASDAQ:HURN) has received an average "Buy" rating from analysts, with a consensus 12-month price target of $184.25. The company recently surpassed earnings expectations, reporting $2.46 EPS against an anticipated $2.17, and saw a 15.7% year-over-year revenue increase to $475.04 million. …

Odigma Consultancy profit rises 40% in Q1FY27; AGM set for Sep 10

Bowman Consulting (BWMN) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Peninsula Energy (ASX:PEN) Shares Slip as Investors Assess Nuclear Energy Trends

Insulet (PODD) Stock Sinks As Type 2 Stumble Clouds Strong Growth

The Top 5 Analyst Questions From FTI Consulting’s Q2 Earnings Call

FTI Consulting's Q2 results showed steady revenue growth but missed profitability expectations due to higher SG&A expenses, leading to a negative market reaction. Analysts questioned management on the impact of the Middle East, restructuring trends, capital deployment, guidance range, and drivers of EBITDA improvement. …

Insulet Reports Second Quarter 2026 Results

Insulet Corporation announced strong financial results for the second quarter of 2026, with revenue reaching $801.7 million, a 23.5% increase year-over-year. The growth was driven by a 24.6% rise in Omnipod revenue, reflecting expanding global access for its tubeless insulin pump technology, including launches …

Insulet (PODD) Is Down 21.9% After Cutting 2026 Revenue Outlook On Weaker Type 2 Retention

In early August 2026, Insulet Corporation reported Q2 results showing US$801.7 million in sales and US$95.0 million in net income, then issued new guidance calling for total GAAP revenue growth of 17%–19% for Q3 2026 and 21%–23% for full-year 2026. At the same time, …

Insulet Corporation Q2 2026 Earnings Call Summary

Insulet Corporation Q2 2026 Earnings Call Summary - Moby Strategic Pivot in the Type 2 Diabetes Market Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 …

Insulet Earnings: Solid Quarterly Results Give Way to Impending Deceleration in Second Half

Insulet Corporation (PODD) PT Lowered to $180 at Stifel

Stifel analyst Jonathan Block has lowered the price target for Insulet Corporation (NASDAQ: PODD) to $180.00 from $225.00. The analyst, however, maintained a previous rating for the company. This article is marked as premium content and requires a subscription to view the full details.

Insulet Stock Crashes as Tiny Guidance Cut Changes the Story

This article first appeared on GuruFocus. Insulet (NASDAQ:PODD), the company behind the Omnipod tubeless insulin pump, got hammered nearly 19% on Wednesday even after delivering a quarter that easily cleared Wall Street's bar. Revenue jumped to $801.7 million, up almost 23% in constant currency …

Insulet Corp. stock underperforms Wednesday when compared to competitors

Insulet Corp. (PODD) shares fell 20.12% on Wednesday, closing at $133.26. This decline occurred during a mixed trading session where the Dow Jones Industrial Average rose, but the S&P 500 Index fell. This marks the second consecutive day of losses for the stock.